# EDGAR Filing Document

**Accession Number:** 0001708331
**File Stem:** 0001213900-23-012605
**Filing Date:** 2023-2
**Character Count:** 4552
**Document Hash:** 18b53747f67df4f478daac1a52e8eb35
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-012605.hdr.sgml**: 20230217

**ACCESSION NUMBER**: 0001213900-23-012605

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230217

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230217

**DATE AS OF CHANGE**: 20230217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Virpax Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001708331
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 821510982
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40064
- **FILM NUMBER:** 23640459

**BUSINESS ADDRESS:**
- **STREET 1:** 1554 PAOLI PIKE #279
- **CITY:** WEST CHESTER
- **STATE:** PA
- **ZIP:** 19380
- **BUSINESS PHONE:** 484-875-3195

**MAIL ADDRESS:**
- **STREET 1:** 1554 PAOLI PIKE #279
- **CITY:** WEST CHESTER
- **STATE:** PA
- **ZIP:** 19380

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Virpax Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20170602

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

 **Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 17, 2023**

**Virpax Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40064** | **82-1510982** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission File Number) | (I.R.S. Employer<br> Identification No.) |

---

**1055 Westlakes Drive, Suite 300**

**Berwyn, PA 19312**

(Address of principal executive offices) (Zip Code)

**(610) 727-4597** 

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Title of Each Class:** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Trading Symbol** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Name of Each Exchange on which Registered** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock, par value $0.00001 per share | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VRPX | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events.**

On February 16, 2023, Virpax Pharmaceuticals, Inc. (the "Company") received a letter from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company's shares of common stock had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, the Company's common stock had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), and that the matter is now closed.

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **VIRPAX PHARMACEUTICALS, INC.** | **VIRPAX PHARMACEUTICALS, INC.** |
| Dated: February 17, 2023 | By: | */s/ Christopher Chipman* |
|  |  | Christopher Chipman |
|  |  | Chief Financial Officer |

---